|
|||||
|
|
Managing immune dysregulation resulting from immune checkpoint inhibitors: impact of the ASCO guidelines and key take-homes for immunologists |
|
| Authors: | Sang T Kim |
| Affiliation: | Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA |
| Abstract: | |
| Keywords: | Cancer immunotherapy immune checkpoint inhibitors immune-related adverse events clinical practice guidelines toxicity |
